Peripheral Neuropathy Trial, Recruiting NCT06550596 Sponsor: Axolotl Biologix Condition: Peripheral Neuropathy
Back to Peripheral Neuropathy

Peripheral Neuropathy Trial, Recruiting

NCT06550596
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be 18 years of age or older.
  • You must have been diagnosed with type 1 or type 2 diabetes.
  • You must have a foot ulcer that measures between 1.0 cm² and 5.0 cm² in size after any wound cleaning has been done.
  • Your foot ulcer must have been present for at least 4 weeks but no longer than 52 weeks before your first screening visit.
  • Your ulcer must be on the foot, with at least half of it located below the ankle bone.
  • Your ulcer must be of a certain depth (reaching at least through the skin layers into the fat beneath, and possibly into muscle), but must not expose any tendon or bone (confirm with trial site).
  • The blood flow to your affected leg and foot must be adequate, confirmed by one of several standard tests done within 3 months before screening (confirm with trial site).
  • If you have more than one foot ulcer, they must be at least 2 cm apart from each other.
  • You must be willing to use the prescribed pressure-relieving footwear or device for the entire study.
  • You must be able to attend weekly study visits as required.
  • You must be willing and able to give your informed consent to take part.

Who may not be able to join:

  • People who are not expected to live longer than 6 months are not eligible.
  • People whose foot ulcer is caused by something other than diabetes are not eligible.
  • People whose target ulcer is currently infected, or who have a skin infection (redness and swelling) around the ulcer, are not eligible.
  • People who have a bone infection related to the target ulcer are not eligible.
  • People who currently need antibiotic tablets or injections for any infection — either in the ulcer or elsewhere in the body — are not eligible.
  • People who are taking immune-suppressing medications or chemotherapy drugs are not eligible (this includes steroid medications above a certain dose).
  • People who have had steroid cream or ointment applied directly to the ulcer within the past month are not eligible.
  • People who have had a partial amputation on the affected foot that makes it difficult to properly relieve pressure from the ulcer are not eligible.
  • People whose ulcer has already shrunk by more than 20% in the 2 weeks before the first screening visit are not eligible.
  • People whose ulcer shrinks by 20% or more during the 2-week screening period before the study officially begins are not eligible.
  • People who are considered malnourished based on a standard nutrition assessment score are not eligible.
  • People who have an active or inactive Charcot foot condition (a serious foot deformity related to nerve damage) that makes it hard to properly relieve pressure from the ulcer are not eligible.
  • Women who are pregnant or planning to become pregnant within the next 6 months are not eligible.
  • People with severe kidney disease who require dialysis are not eligible.
  • People who, in the opinion of the study doctor, have a medical or mental health condition that could affect study results are not eligible.
  • People who have received hyperbaric oxygen therapy (a specialised oxygen treatment) or certain advanced wound care products within the 30 days before screening are not eligible.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 888-960-1343

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Axolotl Biologix
Registry
ClinicalTrials.gov
Start date
23 September 2024
Est. completion
1 October 2025

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Efficacy of dhAM + SOC vs SOC

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov